Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21263831 | 0.95 | SLC29A1 (0.34) | SLC29A1 | |
| SCHEMBL21263916 | 0.83 | STING1 (0.35) | STING1 | |
| SCHEMBL25688763 | 0.78 | STING1 (0.41) | STING1 | |
| SCHEMBL20691351 | 0.78 | STING1 (0.44) | STING1 | |
| SCHEMBL22349195 | 0.78 | STING1 (0.35) | STING1 | |
| SCHEMBL21264010 | 0.76 | STING1 (0.34) | STING1 | |
| SCHEMBL20691310 | 0.74 | STING1 (0.40) | SLC29A1STING1 | |
| SCHEMBL25688781 | 0.74 | STING1 (0.43) | STING1 | |
| SCHEMBL24321999 | 0.72 | SLC29A1 (0.37) | SLC29A1 | |
| SCHEMBL24322109 | 0.72 | STING1 (0.34) | SLC29A1STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | SLC29A1 537/4885STING1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.